Role of Androgen Receptor Variant 7 in progression to Castration Resistant Prostate Cancer
Jay Hofweber Introduction. Prostate cancer (PC) is the second-leading cause of cancer-related death among males in the United States.1 10-20% of prostate cancer patients develop castration-resistant prostate cancer (CRPC) within approximately 5 years with a median survival from 9 to 30 months.2 Progression to CRPC results from failure of androgen…